About the Authors

Joshua W. Wang

Contributed equally to this work with: Joshua W. Wang, Rosie Jiang

Affiliation Department of Pathology, The Johns Hopkins University, Baltimore, Maryland, United States of America

Rosie Jiang

Contributed equally to this work with: Joshua W. Wang, Rosie Jiang

Affiliation Department of Pathology, The Johns Hopkins University, Baltimore, Maryland, United States of America

Shiwen Peng

Affiliation Department of Pathology, The Johns Hopkins University, Baltimore, Maryland, United States of America

Yung-Nien Chang

Affiliations Research and Development Department, Papivax LLC, Rockville, Maryland, United States of America, Immunotherapy Division, Papivax Biotech Inc., Taipei, Taiwan, Republic of China

Chien-Fu Hung

Affiliation Department of Pathology, The Johns Hopkins University, Baltimore, Maryland, United States of America

Richard B. S. Roden

roden@jhmi.edu

Affiliations Department of Pathology, The Johns Hopkins University, Baltimore, Maryland, United States of America, Department of Oncology, The Johns Hopkins University, Baltimore, Maryland, United States of America, Department of Gynecology and Obstetrics, The Johns Hopkins University, Baltimore, Maryland, United States of America

Competing Interests

We have read the journal's policy and have the following competing interests. Yung-Nien Chang is an employee of Papivax Biotech Inc. and holds stock options, and is a member of Papivax LLC. Richard Roden is an inventor of patents (20090047301 Papillomavirus L2 N-Terminal Peptides for the Induction of Broadly Cross-Neutralizing Antibodies and 20100297144 MULTITYPE HPV PEPTIDE COMPOSITIONS AND METHODS FOR TREATMENT OR PREVENTION OF HUMAN PAPILLOMAVIRUS INFECTION) licensed to Shantha Biotechnics Ltd., GlaxoSmithKline, PaxVax, Inc. and Acambis, Inc. Richard Roden has received research funding from Sanofi Pasteur, Shantha Biotechnic and GlaxoSmithKline, is a member of Papivax LLC, has Papivax Biotech Inc. stock options and is a member of Papivax Biotech Inc.'s Scientific Advisory Board. Papivax Biotech Inc. has licensed technology developed by Chien-fu Hung (7,342,002 Molecular vaccine linking an endoplasmic chaperone polypeptide to an antigen). These arrangements have been reviewed and approved by the Johns Hopkins University in accordance with its conflict of interest policies. This does not alter our adherence to all the PLoS ONE policies on sharing data and materials.

Author Contributions

Conceived and designed the experiments: JWW RJ SP YNC CFH RBSR. Performed the experiments: JWW RJ SP CFH. Analyzed the data: JWW RJ SP YNC CFH RBSR. Contributed reagents/materials/analysis tools: YNC CFH RBSR. Wrote the paper: JWW RJ SP YNC CFH RBSR.